786sek
2,7 %
Date:2024-12-20Time:17:29:34Latest report:Q3-2024List:Small CapTicker:VICO
Market Cap:1 834 msekEnterprise Value:1 454 msekNet Sales:104,2 msekEarnings:-196,4 msekEmployees:0ISIN:SE0007577895

Ratios

10-year key figure history for Vicore Pharma turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Vicore Pharma with index and moving average MA50 and MA200.

Stockprice:7,86
MA50:8,01
MA200:14,33
Price/MA200:-45,4 %
RSI (14):50,9
Price/MA50:-2,4 %

Description

Vicore Pharma Holding AB is as a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF. The company also has an investigational medical device in clinical development namely, Almee which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.

Pharmaceuticals